NATURAL REPLACEMENT THERAPY FOR
AUTOIMMUNE DISEASE

Contact Us
IMMUNOMODULATORY
REGENERATIVE
Developing First-in-Class Dual Immunomodulatory and Regenerative Therapeutics for Autoimmune Diseases

Background

From the discoverer of ‘lacritin’ and cofounder of ‘TearSolutions, Inc’, we now know that lacritin is not only on the eye but also in blood. Further, it is necessary for the health of pancreatic islets, is deficient in type 1 diabetics and prevents stage 2 and early stage 3 type 1 diabetes in preclinical models.

Autoimmune Diseases

Regenpep’s dual immunomodulatory and regenerative activity is suspected to have broad application. For proof of concept, our initial focus is on type 1 diabetes. Its regenerative activity on human and mouse islets may benefit type 2 diabetics.

Our Solution - Computer Generated Regenpep Library

An algorithm was created by a former Google Senior Software Engineer. This identified two million candidate therapeutics. Each was screened on a supercomputer through a proprietary in siico screening pipeline for novelty, structure and protease insensitivity. Successes were subjected to biological validation to form the RegenPep Library. RegenPep introduced preclinically by subcutaneous injection is both: (i) immunomodulatory by blocking the formation of the T- and B- inflammatory cells that attack islet cells, and (ii) regenerative for islet endocrine cells, particularly the insulin secreting beta cells.

Background

From the discoverer of ‘lacritin’ and cofounder of ‘TearSolutions, Inc’, we now know that lacritin is not only on the eye but also in blood. Further, it is necessary for the health of pancreatic islets, is deficient in type 1 diabetics and prevents stage 2 and early stage 3 type 1 diabetes in preclinical models.

Autoimmune Diseases

Regenpep’s dual immunomodulatory and regenerative activity is suspected to have broad application. For proof of concept, our initial focus is on type 1 diabetes. Its regenerative activity on human and mouse islets may benefit type 2 diabetics.

Our Solution - Computer Generated Regenpep Library

An algorithm was created by a former Google Senior Software Engineer. This identified two million candidate therapeutics. Each was screened on a supercomputer through a proprietary in siico screening pipeline for novelty, structure and protease insensitivity. Successes are being subjected to biological validation to form the RegenPep Library. RegenPep introduced preclinically by subcutaneous injection is both: (i) immunomodulatory by blocking the formation of the T- and B- inflammatory cells that attack islet cells, and (ii) regenerative for islet endocrine cells, particularly the insulin secreting beta cells.

PROBLEMS WITH CURRENT TREATMENT
OF TYPE 1 DIABETES

  • Jane Brody in the New York Times ('19) writes 'Diabetes, whether Type 1 or Type 2, may be the most underappreciated, misunderstood and poorly treated of all common medical problems, and many of the more than 30 million Americans [Type 1 & Type 2] affected by it are paying dearly with their health and lives as a result.'
  • In 2021 the CDC estimated that type 1 diabetes afflicted 304,000 US children under the age of 20 years and 1.7M adults 20 years or older.
  • Globally the numbers were respectively 1.5M and 7M.
  • Although injectable insulin is helpful, type 1 diabetics continue to suffer from a markedly elevated risk of stroke, heart attack, kidney failure and limb amputation.
  • Also elevated is the risk of blindness associated with diabetic peripheral neuropathies, nephropathy and blood vessel damage.
  • Further, per Gabriel Gregory et al in Lancet Diabetes Endocrinol '22, the 'remaining [mean] life expectancy of a 10-year-old diagnosed with type 1 diabetes in 2021' in low-income countries is 13 years.
  • Newly FDA approved anti-CD3 immunomodulation can delay the onset of type 1 diabetes, an important advance; however it is not regenerative.
Regenpep uniquely: suppresses or eliminates autoimmunity at the level of lymph node immune cell progenitors and is beta cell regenerative.
Contact Us

LEADERSHIP TEAM

Innovation through quality science

Ken L. Brayman, MD, PhD

Cofounder and Chief Scientific Officer
Read Bio

Gordon W. Laurie, PhD

Cofounder and Chief Technical Officer
Read Bio

Colin M. Rolph

Chief Financial Officer
Read Bio
315 Old Ivy Way, Suite 301
Charlottesville, Virginia 22903
IsletRegen CFO Colin Rolph:
crolph@isletregen.com
434-951-0444

GET IN TOUCH

    © IsletRegen 2024 All Rights Reserved.

    Ken L. Brayman, MD, PhD

    Cofounder and Chief Scientific Officer
    Dr. Brayman cofounded IsletRegen with Gordon Laurie and Mingyang Ma. Dr. Brayman is a Professor of Surgery and Biomedical Engineering at the University of Virginia. His surgical practice emphasizes pancreas and islet transplantation for severe diabetics. Dr. Brayman has a long-time research interest in curing type 1 diabetes and runs an active research lab. At UVA, he is Director both of Kidney, Pancreas and Islet Transplant Programs, and the Center for Cellular Therapy and Biologic Therapeutics.

    Gordon W. Laurie, PhD

    Cofounder and Chief Technical Officer
    Dr. Laurie cofounded IsletRegen with Ken Brayman and Mingyang Ma, and is also the cofounder/CSO of TearSolutions. Gordon is a Professor of Cell Biology and Biomedical Engineering at the University of Virginia. He invented RegenPep1 and both discovered and worked out its duo immunosuppressive and regenerative benefit in diabetes with Mingyang and Ken. With almost thirty-two years of NIH R01 funding, Dr. Laurie discovered, named and worked out mechanisms of action of ‘lacritin’ that underpins TearSolutions’ topical therapeutic for autoimmune dry eye disease.

    Colin M. Rolph

    Chief Financial Officer
    Colin is a serial, early-stage CFO, and CFO of Tearsolutions. Through his leadership, numerous local companies have advanced through angel and institutional investment. Mr. Rolph manages a venture investment fund Tall Oaks Capital that focuses on medical devices, biotechnology and IT investments and is an angel investor. Mr. Rolph holds a B.S. from the Rochester Institute of Technology.